银信科技 reported revenue of ¥0.70B for the period ended 2026-06-30, -16.1% year on year. Net income was ¥0.02B, a 2.4% net margin on a 17.9% gross margin. The largest revenue line is IT基础设施 at 46% of the total. Free cash flow for the period was ¥0.04B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.70B | -16.1% |
| Gross profit | ¥0.13B | — |
| Operating income | ¥0.03B | — |
| Net income | ¥0.02B | -65.1% |
| Gross margin | 17.9% | Net margin 2.4% |
| Revenue Q/Q | -19.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| IT基础设施 | ¥0.33B | 46.4% |
| 系统集成服务 | ¥0.32B | 46.0% |
| 算力服务业务 | ¥0.05B | 7.0% |
| 软件开发与销售 | ¥0.00B | 0.6% |
| 其他(补充) | ¥0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.58B | 82.1% |
| R&D | ¥0.03B | 4.9% |
| SG&A | ¥0.07B | 9.7% |
| Tax & other | ¥0.01B | 1.4% |
| Item | Amount |
|---|---|
| Total assets | ¥2.51B |
| Total liabilities | ¥0.90B |
| Shareholders' equity | ¥1.61B |
| Equity / assets | 64.2% |
| Operating cash flow | ¥0.04B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.04B |
| Cash conversion (OCF / net income) | 840% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
洲明科技 ・ 金城医药 ・ 开尔新材 ・ 方直科技 ・ 上海新阳 ・ ST美晨 ・ 冠昊生物 ・ 东宝生物 ・ 飞力达 ・ 瑞丰光电 ・ 佳云科技 ・ 瑞丰高材
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies